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A phase II study of erlotinib (E) and bevacizumab (B) in patients 
(pts) with previously untreated stage IIIB/IV non-small-cell lung 
cancer (NSCLC)
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Background: In advanced NSCLC, E and B either as a single agent 
(E) or in combination with chemotherapy (B) have shown to improve 
survival. Combinations of targeted agents may prove to be effective 
and better tolerated than chemotherapy. 
Methods: This is a multicenter 2-stage phase II study (Simon’s optimal 
design; p0=40%, p1=60%, α=0.05, β=0.20) with early stopping rule 
.The primary endpoint is non-progression (NPR) at 6 weeks. When 
24/46 pts have NPR at 6 wks the treatment will be declared to have suf-
ﬁcient activity for further testing. 
Pts (PS 0-2) with advanced non-squamous NSCLC who had received 
no prior systemic anti-tumour therapy were treated with E (150mg/day) 
plus B (15mg/kg every 21 days) until disease progression or unac-
ceptable toxicity, An imaging protocol including CT, DCE-MRI and 
FDG/H20 PET was performed at weeks -1,3 and 6.
Results: Between 02/06 and 02/07, 43 pts were included; 33 evaluable 
for safety and efﬁcacy, 10 pts are too early. 
Demographics: M/F: 17/16; median age 60 (range 34-80); PS 0/1/2: 
16/13/4; smoking status: current/former/never 13/16/4. Twenty-ﬁve 
pts had stage IV disease. The most common treatment-related adverse 
events (all grades) were: rash (32%) and diarrhea (18%). Hypertension 
was observed in 2.9% of courses. Grade 3/4 adverse events (≥5%) con-
sisted of rash (31% of patients). There was 1 probable treatment-related 
death. Six pts withdrew early from the study, 2 due to toxicity (trom-
bosis and mucositis), 2 due to death (1 death for unknown reason, 1 
due to pneumonia), 2 for treatment unrelated reasons. 5 pts had E dose 
modiﬁcations for toxicity and 5 delay of B mainly for logistic reasons. 
Rate of NPR at 6 weeks 76% (25/33) with 10 (30%) PR. The median 
follow-up is 7.2 months (95% CI 4.3-8.6 months). Median TTP: 5.5 
months (95% CI 1.3 - 6.2), At this interim analysis 22/33 patients are 
alive,16/31 patients are without disease progression and 13/32 patients 
are on protocol treatment .
Conclusions: E + B was well tolerated, with a low rate of grade 3/4 ad-
verse events and no unexpected toxicities. The 75% no progression rate 
justiﬁes phase III testing in untreated advanced non-squamous NSCLC 
against platinum based chemotherapy. Updated results including cor-
relative imaging studies will be presented.
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Background: Some of the patients with stage I lung cancers can not 
be treated surgically because of low lung function and/or other reasons, 
development of non-surgical curative modalities are expected to 
decrease mortality from lung cancer. Carbon ion radiotherapy (CIRT) 
is a promising modality because of its excellent dose localization and 
high biological effects on a tumor. From 1994 to 1999, we conducted a 
phase I / II clinical trial for stage I non-small cell lung cancer (NSCLC) 
by using carbon ion beams alone. And demonstrated an optimal dose 
of 90GyE in 18 fractions over 6 weeks and 72GyE in 9 fractions over 3 
weeks, achieving more than 95% local control with minimum pulmo-
nary damage. In the present study, we conducted a phase II clinical trial 
for stage NSCLC to determine the local control and the survival rates.
Methods: One hundred twenty-nine patients with 131 primary lesions 
were treated from 1999 to 2003 in National Institute of Radiologi-
cal Sciences, Research Center Hospital for Charged Particle Therapy, 
Japan. The patients consisted of 37 females and 92 males, with a mean 
age of the patients 74.5 years. The T1 and T2 numbers were 72 and 59, 
respectively, and the average tumor size in diameter was 31.5 mm. By 
histology, the tumors broke down into 85 adenocarcinomas, 43 squa-
mous cell carcinomas, two large cell carcinomas and one adenosqua-
mous cell carcinoma. A primary tumor was treated with carbon beam 
alone using the ﬁxed total dose of 72GyE in 9 fractions over 3 weeks, 
or 52.8GyE for stage IA, 60GyE for stage IB over one week. Most of 
targets were irradiated from obliquely from four directions. A respira-
tory-gated irradiation system was used for irradiation in each case. 
Local control and survival were determined by using the Kaplan-Meyer 
method and the data were statistically processed by using the long-rank 
test (the signiﬁcance level was 0.05).
Results: The cumulative local control rate for all lesions was 94.7% at 
58 months after CIRT. There was no statistical difference in the local 
control rate between T1 and T2 (p=0.061), and between the histolo-
gies (squamous cell carcinoma vs. non-squamous cell carcinoma) 
(p=0.077). Overall 5-year survival rates after CIRT were 68.7% in stage 
IA (n=69), 46.4% in stage IB (n=56). No toxic reactions were observed 
in the skin and no adverse effects worse than grade III were detected.
Conclusions: Carbon beam radiotherapy, a new therapy modality with 
superior beneﬁts in terms of QOL and ADL, has been proven to be a 
valid alternative to surgery for stage I NSCLC and to offer particular 
beneﬁts especially for the poor surgical candidates.
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Background: In recent years, it has become clear that tumors are not 
homogeneous, also for radioresistance. The identiﬁcation of areas of 
radioresistance within the same tumor is therefore of great interest, for 
it may allow selective boosting of these zones. This study therefore 
addressed two critical questions needed for escalating dose to speciﬁc 
areas within the tumor: 1. Where does the residual disease occur after 
treatment based on FDG PET imaging? 2. Does the high FDG uptake 
zone remain stable within the tumor during a course of radiotherapy? 
Methods: 1. Location of residual disease within the tumor. Six patients 
with inoperable NSCLC, stage I-III, treated with radical radiotherapy, 
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showing residual disease on FDG-CT-PET scan 70 days post-treat-
ment, were studied. The volume of residual disease was deﬁned by the 
area with a Standardized Uptake Value (SUV) higher than mediastinal 
uptake. Overlap fractions (OF) were calculated between this residual 
disease volume and the original tumor, with several SUV threshold 
based auto-delineations on a FDG-CT-PET scan before radiotherapy.
2. Stability of the high FDG-uptake areas during radiotherapy. Twenty-
three patients underwent repeated FDG-CT-PET scans before and one 
and two weeks after the start of radiotherapy. Tumors with volumes 
>70 cm3 (n=9) were used to assess heterogeneity in FDG-uptake. OF’s 
were used to demonstrate the stability of the high FDG uptake regions 
(50% SUV volume) during treatment.
Results: 1. Location of residual disease within the tumor. The loca-
tion of the residual disease was nearly completely (OF > 95%) within 
the contour of the original tumor, deﬁned as the 34% threshold SUV 
contour, based on the source-to-background ratio (van Baardwijk et al 
Int J Radiat Oncol Biol Phys, 2007). As depicted in ﬁgure 1, on aver-
age (bold black line) the residual had an OF of more than 80% with 
the 50% threshold of the pre-treatment PET scan. This indicates that 
residual disease occurs within the high-uptake region of the original 
tumor and therefore, escalating dose to this speciﬁc area is likely to 
improve local control.
Figure 1. Overlap Fractions of the residual tumor with the SUV threshold of 
the PET scan before radiotherapy.
2. Stability of the high FDG-uptake areas during radiotherapy The 
mean OF’s of the high uptake zone during therapy were 75.7 ± 10.9% 
at day 7 and 67.5 ± 16.4% at day 14 during treatment. So, the loca-
tion of the high FDG uptake region within the tumor during treatment 
remained the same. 
Conclusions: Residual disease within the primary tumor is not due to 
geographic miss. The location of residual disease corresponds with the 
original 50% highest FDG uptake before radiotherapy.
This location of the high FDG uptake within the tumor remained stable 
during radiotherapy. Boosting of tumor sub-volumes may thus be 
feasible and potentially beneﬁcial, using only a FDG-PET scan before 
therapy.
D7-06 Novel therapeutics II, Thu, 12:30 - 14:15
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Background: Adjuvant and neoadjuvant chemotherapy play a role in 
optimising long-term outcome of patients with resectable non-small-
cell lung cancer (NSCLC). The epidermal growth factor receptor 
(EGFR) is a receptor tyrosine kinase that is overexpressed in NSCLC. 
Cetuximab, a monoclonal antibody, targets the extracellular domain 
of the EGFR preventing ligand binding. Preclinical data and phase II 
evidence in advanced NSCLC suggest that cetuximab potentiates the 
activity of conventional cytotoxic agents.
Methods: Patients with histologically conﬁrmed resectable stage 
IB-IIIA NSCLC and adequate end-organ function, giving informed 
written consent were eligible. Patients received 3-weekly cycles of 
cisplatin 80mg/m2 d1, gemcitabine 1250mg/m2 d1 & d8 and cetuximab 
400mg/m2 loading dose, thereafter weekly 250mg/m2. The primary 
endpoint is response rate (radiological and pathological). Secondary 
endpoints are safety and tolerability of the combination, resection rate 
following therapy, overall survival and relapse free survival. In addition 
serum, plasma and white blood cells are being collected before, during 
and after therapy from all patients. For proteomic analysis undenatured 
and unfractionated pretreatment serum samples underwent Surface 
Enhanced Laser Desorption/Ionisation Time of Flight Mass Spec-
trometry (SELDI-TOF MS) proﬁling using a strong anion exchange 
ProteinChip® array (Q10 Array).
Results: 30 patients have been recruited to date (19 men, 11 women), 
median age 64 (range 29-77), 24 patients stage I, 2 patients stage II, 4 
patients stage III. 27 patients have completed treatment and are evalu-
able for response. The overall response rate is 76% including CR - 1 
patient, PR -18 patients, SD -7 patients, PD -1 patient. The most com-
mon toxicity was skin rash (100%). The commonest grade 3/4 toxicities 
were neutropenia (52%) and thrombocytopenia (36%). There were 3 
grade 3 and 4 grade 4 cardiovascular toxicities in patients with signiﬁ-
cant co-morbid cardiovascular toxicities including peripheral arterial 
ischemia (2), cerebrovascular accident (3) and myocardial infarction 
(2). One patient was withdrawn from study because of complicated pe-
ripheral ischemia. Using ciphergen express software serum proteomic 
analysis in 21 patients divided into two groups -radiological responders 
vs non-responders - revealed six differentially expressed peaks.
Conclusions: The response rate appears higher then that reported for 
neoadjuvant chemotherapy in other studies. Patient accrual continues. 
Ongoing biomarker studies may identify those patients most likely 
to beneﬁt from induction treatment. In order to maximise the protein 
peaks we have depleted our samples of IgG and Albumin. We are 
currently proﬁling these denatured and depleted samples on three 
ProteinChip® arrays. 
